This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/5/2026
Good afternoon, everyone. Thank you for standing by. Welcome to SitomX Therapeutics' third quarter 2026 financial results call. Please be advised that today's call is being recorded. I would now like to hand the call over to your host for today, Chris Ogden, SitomX's chief financial officer. Please go ahead.
Thank you. Good afternoon, and thank you for joining us. Before we begin, I would like to remind everyone that during this call, we'll be making forward-looking statements. Because forward-looking statements relate to the future, they're subject to inherent uncertainties and risks that are difficult to predict, and many of which are outside of our control. Important risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov. Except as required by law, we undertake no obligation to update any forward-looking statements whether as a result of new information, future developments, or otherwise. Earlier this afternoon, we filed our quarterly report on Form 10-Q for Q3 2026 and issued a press release with a summary of our third quarter 2026 financial results and business highlights. We encourage everyone to read today's filing and press release. Additionally, the press release, recording of this call, and our SEC filings can be found under the Investors and News section of our website. With me on the call today is Dr. Sean McCarthy, CytomX's Chief Executive Officer and Chairman. Sean will provide an update on our pipeline and company progress before I cover the financials for the quarter. We will then conclude with a Q&A session. With that, I'll turn the call over to Sean.
Thanks, Chris, and good afternoon, everyone. We're very pleased to be here today to provide an update on our third quarter developments and what continues to be a highly productive year for cytomics as we advance our lead program, Varsetta-M, towards its first potential registrational study in the first half of 2027. Varsetta-M is an EPCAM-targeting TOPO1 antibody drug conjugate with strong potential in colorectal cancer and potentially other solid tumors. Importantly, to our knowledge, Varsetta M is first in class as the only EPCAM-directed ADC in clinical development. Varsetta M has been intentionally designed and uniquely enabled by our ProBody platform, creating a significant opportunity for differentiation and long-term value creation. Strategically, we are initially developing Varsetta M in metastatic colorectal cancer as the lead indication. Our sense of urgency for Varsetta M is driven by the significant unmet need in colorectal cancer, which is the second leading cause of cancer death in the United States and worldwide. Varsetta M is on the leading edge of ADC innovation in CRC and has the potential to be one of the first monotherapy ADCs to market for the treatment of this very challenging cancer type. In terms of commercial potential, there are an estimated 35,000 addressable patients in the United States with third line or later CRC. Given the anti-cancer activity we have reported previously across an unselected late stage patient population and the limited clinical benefit of existing therapies for these patients, we see considerable opportunity for Varsetta M. Based on VarsettaM's unique profile, we are actively advancing our development program across three strategic areas of priority. First, we aim to move VarsettaM monotherapy into a registrational study in the first half of next year, enabling a potential first approval and meaningful market opportunity in metastatic CRC. Second, we continue our development of VarsettaM in combinations, including with Bevacizumab and with early aligned chemotherapy regimens with the goal of replacing current standard of care. And third, we have started to evaluate Varsetta-M's pan-tumor potential across multiple EPCAP-expressing cancers, initially in additional gastrointestinal indications. The monotherapy Varsetta-M phase one study has enrolled more than 100 patients across dose escalation, expansion, and Optimization Cohorts. As previously reported, patients enrolled in the phase one study have been heavily pretreated with most patients having received three or more prior treatments in the metastatic setting. In March, we reported encouraging progression pre-survival at doses of 8.6 and 10 milligrams per kilogram that exceeded current standard of care. We also shared our increasing understanding of the safety profile of Varsetta M particularly how to lower and manage rates of high grade diarrhea. This initial experience with Varsetta M in very late line patients will provide us with a highly relevant data set to enable monotherapy dose selection and inform the potential first registrational study design. Most recently, we have been highly focused on dose optimization, evaluating two doses, 8.6 and 10 milligrams per kilogram given every three weeks with adjusted ideal body weight dosing and upfront prophylaxis to manage gastrointestinal adverse events. We anticipate providing an integrated update in January across the phase one study, including our potential registrational strategy and the data that underpin our plans. It's important to note here that we expect this next update to provide the first look at overall survival for Varsetta M, which we anticipate will be the primary endpoint in our initial registration study. We look forward to providing this next update in the near term. Now moving on to the Varsetta-M combination development program. Our ongoing phase one study evaluating Varsetta-M in combination with Bevacizumab continues to enroll late line CRC patients to assess dose and safety. We view this combination as a foundational first step in evaluating Varsetta-M's potential in early-aligned CRC. Subject to data from the ongoing Phase 1 study, we anticipate moving to early-aligned CRC patients in the future evaluation of this combination, and we anticipate reporting initial clinical data from the Bevacizumab combination in the first half of 2027. To also enable the use of Varsetta M in earlier lines of CRC therapy, We remain on track to initiate a study evaluating Varsetta-M in combination with Bevacizumab, 5-Fluorouracil, and Leucovorin by the end of the year. This study will be a new Phase 1-2 trial that would enroll second-line CRC patients once Phase 1 dose finding is successfully completed. We believe these Varsetta-M combination studies have the potential to inform future development options and look forward to providing initial updates starting next year. Now moving to the development of Varsetta M outside of CRC, our strategy is to develop and ultimately commercialize Varsetta M across multiple EPCAM-expressing solid tumors. And we have recently initiated phase one cohorts in gastrointestinal indications with substantial unmet clinical need and that we view as highly complementary to CRC from a commercial perspective. We have initiated cohorts in unselected gastric and gastroesophageal junction cancer, as well as EPCAM-selected pancreatic ductal adenocarcinoma and EPCAM-selected biliary tract cancer. Each of these EPCAM-expressing tumor types currently have limited treatment options in later line settings and may present expedited development pathways for Varsetta M upon clinical proof of concept. Our initial plan is to enroll approximately 20 patients per tumor type to evaluate Varsetta-M's anti-tumor activity and safety before assessing later phase development options. Having focused Varsetta-M exclusively in CRC for the first two years of development, we're very excited to now be evaluating Varsetta-M's broader clinical potential. Now, turning to CX801, our masked interferon alpha 2B program, being evaluated in checkpoint refractory melanoma. We see CX801 as an exciting and broad opportunity to reprogram the immune responsiveness of solid tumors. And we continue to enroll the ongoing phase one study, evaluating CX801 as a monotherapy and in combination with Keytruda. Enrollment in the monotherapy cohort of our phase one study continues. having exceeded dose levels of the approved dose of unmasked interferon alpha 2B. Initial biomarker data for CX801 monotherapy presented previously have reinforced our mechanism of action hypothesis for CX801 in combination with Keytruda. We continue to enroll in the combination cohort and we look forward to sharing initial clinical data from the phase one study in melanoma in the first half of 2027. With those updates, let me now transition the call back to Chris.
You're reading a preview of the CTMX Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing